Pfizer intends to sell fixed- and floating-rate notes in six parts

By Devika Patel

Knoxville, Tenn., Sept. 4 – Pfizer Inc. is preparing to sell a six-part offering of senior notes with fixed- and floating-rate tranches, according to a 424B3 filing with the Securities and Exchange Commission.

There is one tranche of floating-rate notes, with the maturity to be set at pricing.

The fixed-rate notes are due 2021, 2023, 2028, 2038 and 2048.

The floaters are non-callable. The 2021 notes have a make-whole call. The remaining fixed-rate notes will have a make-whole call and then a par call.

BofA Merrill Lynch, Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC and Morgan Stanley & Co. LLC are the joint bookrunners.

Proceeds will be used for general corporate purposes, including to refinance, redeem or repurchase existing debt and to repay a portion of commercial paper.

The biopharmaceutical company is based in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.